SIREN L L C
Q3 2026 Form 13-F
GREENWICH, DELAWARE
CIK 0002005245
· Institutional investment manager
Consolidated report · includes
2 managers
since Q3 2024
$4.2B Reported Value Total
Reported value
$4.2B
Quarter over quarter
-11.3%
Holdings
110
Top-10 concentration
47.3%
Filing Structure
Reports holdings for
- Invus Financial Advisors LLC · File #028-19938 · since Q3 2024
- Invus Group, LLC (not a 13F filer in our records) · File #028-24462 · since Q3 2024
Key People
Named on the latest Form 13-F filing — not necessarily an owner
Raymond Debbane
President
Filing Navigation
13F Metrics
Loading 13F Metrics
Q3 2026 13F record
Q3 2026 13F filing summary
| Period of report | September 30, 2026 |
|---|---|
| Filed | November 12, 2026 |
| Form | 13F-HR |
| Reported value | $4.2B |
| Positions | 110 |
| Change in reported value | -14.4% |
| New positions | 18 |
| Exited positions | 23 |
| Position turnover | 30.8% |
| Top-10 concentration | 47.3% |
13F filings by quarter
| Quarter | Positions | Value |
|---|---|---|
|
Q3 2026 13F
Filed Nov 12, 2026
|
110 | $4.2B |
|
Q2 2026 13F
Filed Aug 13, 2026
|
115 | $4.9B |
|
Q1 2026 13F
Filed May 14, 2026
|
100 | $3.6B |
|
Q4 2025 13F
Filed Feb 13, 2026
|
113 | $3.4B |
|
Q3 2025 13F
Filed Nov 13, 2025
|
115 | $2.6B |
|
Q2 2025 13F
Filed Aug 13, 2025
|
110 | $1.9B |
|
Q1 2025 13F
Filed May 14, 2025
|
116 | $1.8B |
|
Q4 2024 13F
Filed Feb 14, 2025
|
117 | $2.3B |
|
Q3 2024 13F
Filed Nov 13, 2024
|
109 | $2.0B |
Top 20 holdings · Q3 2026
| # | Holding | Reported value | % of portfolio |
|---|---|---|---|
| 1 | SRRK Scholar Rock Holding Corporation | $453.0M | 10.71% |
| 2 | KYMR Kymera Therapeutics, Inc. | $311.3M | 7.36% |
| 3 | ERAS Erasca, Inc. | $193.5M | 4.57% |
| 4 | RVMD Revolution Medicines, Inc. | $174.5M | 4.12% |
| 5 | ONC BeOne Medicines AG | $170.2M | 4.02% |
| 6 | TNGX Tango Therapeutics, Inc. | $169.3M | 4.0% |
| 7 | MANE Veradermics, Incorporated | $160.5M | 3.79% |
| 8 | ARWR Arrowhead Pharmaceuticals, Inc. | $149.9M | 3.54% |
| 9 | EWTX Edgewise Therapeutics, Inc. | $113.8M | 2.69% |
| 10 | RYTM Rhythm Pharmaceuticals, Inc. | $103.4M | 2.44% |
| 11 | BCAX Bicara Therapeutics Inc | $102.4M | 2.42% |
| 12 | PBLS Parabilis Medicines Inc | $96.6M | 2.28% |
| 13 | LXRX Lexicon Pharmaceuticals, Inc. | $83.3M | 1.97% |
| 14 | SYRE Spyre Therapeutics Inc | $77.3M | 1.83% |
| 15 | TYRA Tyra Biosciences, Inc. | $74.3M | 1.76% |
| 16 | COAG Hemab Therapeutics Holdings Inc | $73.0M | 1.72% |
| 17 | AMLX Amylyx Pharmaceuticals, Inc. | $72.2M | 1.71% |
| 18 | ELVN Enliven Therapeutics, Inc. | $67.6M | 1.6% |
| 19 | SEPN Septerna, Inc. | $66.5M | 1.57% |
| 20 | RCUS Arcus Biosciences, Inc. | $62.5M | 1.48% |
Values as reported on the Q3 2026 Form 13F. Every position is in the holdings table below.